Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Depression

Ketamine paired with looking at smiling faces to build positive associations holds promise in treating depression

by Rebecca Price
December 26, 2022
in Depression, Psychedelic Drugs
(Photo credit: Adobe Stock)

(Photo credit: Adobe Stock)

Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

Simple computer exercises using positive words and images designed to boost self-worth can prolong the antidepressant effects of ketamine in people with depression. That’s what my research team and I found in our new study.

Over two decades ago, researchers serendipitously discovered that intravenous ketamine, a widely used anesthetic medication that has been shown to be safe when administered under medical supervision, had rapid-acting antidepressant effects when given at lower doses than is used for anesthesia.

Our study included 154 adult patients with depression. One-third received a single infusion of ketamine and returned a day later to begin four consecutive days – about 30 to 40 minutes total each day – of our novel digital exercises. That is, we showed them repeated pairings of self-related words and images – such as the letter “I” and photos of the patient – paired up repeatedly with positive cues. These include positive words like “good,” “sweet” and “lovable” as well as photos of strangers smiling.

We targeted this period of time within five days of ketamine because we expected ketamine would quickly help restore the brain’s healthy capacity to adjust and learn in response to the environment. The specific exercises we used were designed based on our prior work showing that, shortly after a ketamine infusion, thought patterns related to oneself may become less “stuck” and be more malleable, creating a window of opportunity to improve a person’s sense of self-worth.

The other two-thirds of patients went into one of our two control groups: those who received ketamine followed by a neutral, or placebo, version of computer training, and those who received a saline infusion followed by the real training exercises.

We found that after just a single intravenous infusion of ketamine, patients experienced relief from depression symptoms for at least one month as long as they were assigned to the group that completed the digital exercises within the first five days. Compared with those in the control saline group, both of the groups that received a ketamine infusion experienced substantial relief from depression on the first day, prior to any computer training.

However, whereas the control group who went on to receive the “sham” computer training began to experience the return of depression symptoms in the subsequent 1.5 weeks or so, the group that received ketamine followed by exposure to positive conditioning continued to report decreased depression severity all the way out to the last follow-up interview, one month after ketamine.

The people who got digital training in the absence of ketamine had very little relief from their depression.

Why it matters

Depression is a highly prevalent and disabling condition that exacts a staggering burden on patients, families and communities.

Globally, an estimated 280 million people experience depression. There are numerous effective treatments for depression, including antidepressant medications and psychotherapy.

However, unfortunately, not all patients are helped by such treatments. And accessing them initially, as well as maintaining them over the long haul can be challenging for many patients.

The discovery of ketamine’s rapid-acting antidepressant effects opened up a brand new possibility within psychiatry to begin relieving symptoms within a day. Conventional treatments typically take six to eight weeks to reach a therapeutic effect.

However, a key question is how to keep that relief going without relying solely on repeated ketamine infusions. These can be burdensome and costly for patients and health care systems, and it is important to consider possible risks, such as the potential for drug misuse.

Our study is the first to demonstrate that the rapid effects of ketamine can be made more enduring with simple, portable and automated techniques that would be relatively easy to provide to patients in a wide range of settings.

What’s next

Our initial findings suggest the positive conditioning exercises tripled – at a minimum – the duration of ketamine’s effects. But we don’t yet know how much longer the relief from depressive symptoms may have continued.

Patients in our trial will continue to complete questionnaires about their depression symptoms for an entire year following the infusion, enabling us to gain an initial understanding of just how long this benefit may endure.

Ongoing research is exploring whether similar techniques might help ease suicidality, in the hopes of providing relief in the midst of a suicidal crisis that is both immediate and enduring. Other future research may expand these techniques to additional common forms of psychological suffering, such as anxiety, disordered eating and more.The Conversation

 

This article is republished from The Conversation under a Creative Commons license. Read the original article.

RELATED

Surprising link found between aesthetic chills and political extremism
Anxiety

Single dose of psilocybin provides lasting relief from depression and anxiety in cancer patients

August 27, 2025

Cancer patients with major depression experienced significant and long-lasting improvements after just one psilocybin session, according to new research. Two years later, many showed continued reductions in depression and anxiety, with some requiring no further treatment or medication.

Read moreDetails
Scientists uncover biological pathway that could revolutionize anxiety treatment
MDMA

Psilocybin and MDMA may reset fear-related brain-immune signaling, scientists find

August 25, 2025

Psilocybin and MDMA may do more than alter perception. A study in Nature suggests they also reduce fear by targeting a newly identified immune-brain signaling loop, which becomes hyperactive under chronic stress and contributes to heightened fear responses.

Read moreDetails
Research shows diabetes drug could reduce dementia risk. Here’s how the two diseases may be linked
Depression

Antidepressant withdrawal symptoms may be more common and more severe than some studies suggest

August 22, 2025

A new study challenges previous claims that antidepressant withdrawal is rare or mild. Researchers found that more than half of patients report symptoms when discontinuing, suggesting earlier reviews relying on short-term trials may have underestimated the risks.

Read moreDetails
Neuroscience research shows psychedelics plus psychotherapy can trigger rapid brain changes
Ayahuasca

Near-death visions and DMT trips share eerie similarities — but key differences set them apart

August 17, 2025

A new study comparing near-death experiences with high-dose DMT trips finds striking similarities — and surprising differences — in what people see and feel. The research sheds light on how the brain might shape extraordinary states of consciousness.

Read moreDetails
The neurobiology of trauma: How childhood adversity alters brain development
Depression

Esketamine nasal spray shows rapid antidepressant effects as standalone treatment

August 16, 2025

A new clinical trial suggests that esketamine nasal spray, used alone without oral antidepressants, may reduce depressive symptoms in patients with treatment-resistant depression. The fast-acting treatment showed benefits within 24 hours and sustained effects over four weeks.

Read moreDetails
Specific narcissistic traits appear to heighten veteran PTSD risk
Depression

Depressed individuals have heightened C-reactive protein-to-albumin ratio

August 13, 2025

New research links an elevated C-reactive protein-to-albumin ratio—a blood marker reflecting inflammation and nutrition status—to higher odds of depression. The findings raise the possibility that this widely available biomarker could play a role in mental health screening.

Read moreDetails
Psilocybin might be effective for treatment-resistant depression even with ongoing SSRI use, study suggests
Psychedelic Drugs

Psychedelic experiences may offer a lasting boost in perceived life meaning

August 11, 2025

New research suggests that psychedelics may offer more than momentary insight—they tend to leave people with a stronger sense of meaning in life. Across three studies, participants reported lasting increases in existential fulfillment after psychedelic experiences.

Read moreDetails
Dark Triad personality traits linked to more favorable attitudes toward cognitive enhancement
Alzheimer's Disease

Antidepressant vortioxetine linked to greater cognitive and mood improvements in Alzheimer’s patients

August 9, 2025

A year-long study suggests vortioxetine may offer greater improvements in both cognition and mood for people with Alzheimer’s disease and depression compared to other antidepressants, potentially making it a promising treatment option alongside standard Alzheimer’s therapies.

Read moreDetails

STAY CONNECTED

LATEST

Scientists shocked to find a supposedly harmless virus hiding in brains of Parkinson’s patients

Hostile sexism linked to disapproval of breastfeeding in public

New study suggests breathing polluted air can increase risk of depression, anxiety, and autism

New research finds moderate cognitive impairments in heavy cannabis users

Mobile phone dependence linked to creativity in surprising ways among adolescents

Shock events in 2024 presidential campaign reversed typical online behavior, new study shows

Mindfulness app helps reduce anxiety and stress in autistic adults, study finds

New psychology research identifies a key factor behind support for harsh leaders

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy